Page 109 - AN-3-2

Advanced Neurology X chromosome-mediated risk in Alzheimer’s disease

13. Yan Y, Wang X, Chaput D, et al. X-linked ubiquitin-specific doi: 10.1001/archneur.59.11.1764
peptidase 11 increases tauopathy vulnerability in women. 26. Complete Health Indicator Report of Life Expectancy at Birth.
Cell. 2022;185(21):3913-3930.e19.
Utah Department of Health, Indicator-Based Information
doi: 10.1016/j.cell.2022.09.002 System for Public Health. Available from: https://ibis.health.
utah.gov [Last accessed on 2022 Jul 17].
14. Eissman JM, Dumitrescu L, Mahoney ER, et al. Sex
differences in the genetic architecture of cognitive resilience 27. Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-
to Alzheimer’s disease. Brain. 2022;145(7):2541-2554. predominant age-related TDP-43 encephalopathy (LATE):
Consensus working group report. Brain. 2019;142:1503-1527.
doi: 10.1093/brain/awac177
doi: 10.1093/brain/awz099
15. Davis EJ, Solsberg CW, White CC, et al. Sex-specific
association of the X chromosome with cognitive change 28. Klyucherev TO, Olszewski P, Shalimova AA, et al. Advances
and tau pathology in aging and Alzheimer disease. JAMA in the development of new biomarkers for Alzheimer’s
Neurol. 2021;78(10):1249-1254. disease. Transl Neurodegener. 2022;11:25.
doi: 10.1001/jamaneurol.2021.2806 doi: 10.1186/s40035-022-00296-z
16. Davis EJ, Broestl L, Abdulai-Saiku S, et al. A second X 29. Printzlau F, Wolstencroft J, Skuse DH. Cognitive, behavioral,
chromosome contributes to resilience in a mouse model of and neural consequences of sex chromosome aneuploidy.
Alzheimer’s disease. Sci Transl Med. 2020;12(558):eaaz5677. J Neurosci Res. 2017;95:311-319.
doi: 10.1126/scitranslmed.aaz5677 doi: 10.1002/jnr.23951
17. Armon C, Wolfson S, Margalit R, et al. Estimating the X 30. Wu H, Luo J, Yu H, et al. Cellular resolution maps of
chromosome-mediated risk for developing Alzheimer’s X chromosome inactivation: Implications for neural
disease. J Neurol. 2022;269:2479-2485. development, function, and disease. Neuron. 2014;81:103-119.
doi: 10.1007/s00415-021-10826-w doi: 10.1016/j.neuron.2013.10.051
18. Cannon-Albright LA. Utah family-based analysis: Past, 31. Ormond KE, Mortlock DP, Scholes DT, et al. Human germline
present and future. Hum Hered. 2008;65:209-220. genome editing. Am J Hum Genet. 2017;101:167-176.
doi: 10.1159/000112368 doi: 10.1016/j.ajhg.2017.06.012
19. Kauwe JS, Ridge PG, Foster NL, Cannon-Albright LA. 32. Komor AC, Badran AH, Liu DR. CRISPR-based technologies for
Strong evidence for a genetic contribution to late-onset the manipulation of eukaryotic genomes. Cell. 2017;168:20-36.
Alzheimer’s disease mortality: A population-based study. doi: 10.1016/j.cell.2016.10.044
PLoS One. 2013;8:e77087.
33. Gupta RM, Musunuru K. Expanding the genetic editing
doi: 10.1371/journal.pone.0077087
tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest.
20. Agresti A. Categorical Data Analysis. New York: Wiley; 1990. 2014;124:4154-4161.
21. Furlan G, Galupa R. Mechanisms of choice in X-chromosome doi: 10.1172/JCI72992
inactivation. Cells. 2022;11:535.
34. Omura JD, McGuire LC, Patel R, et al. Modifiable risk
doi: 10.3390/cells11030535 factors for Alzheimer disease and related dementias among
adults aged ≥45 Years - United States, 2019. MMWR Morb
22. García-González P, de Rojas I, Moreno-Grau S,
et al. Mendelian randomisation confirms the role of Mortal Wkly Rep. 2022;71:680-685.
Y-chromosome loss in Alzheimer’s disease aetiopathogenesis doi: 10.15585/mmwr.mm7120a2
in men. Int J Mol Sci. 2023;24(2):898.
35. Power MC. Growing evidence links air pollution exposure
doi: 10.3390/ijms24020898 to risk of Alzheimer’s disease and related dementia. Brain.
2020;143:8-10.
23. Rhie A, Nurk S, Cechova M, et al. The complete sequence of
a human Y chromosome. Nature. 2023;621:344-354. doi: 10.1093/brain/awz396
doi: 10.1038/s41586-023-06457-y 36. Van Dyck CH, Swanson CJ, Aisen A, et al. Lecanemab in
early Alzheimer’s disease. N Engl J Med. 2023;388:9-21.
24. Armon C, Traynor BJ. High BMI is associated with low ALS
risk: What does it mean? Neurology. 2019;93:189-191. doi: 10.1056/NEJMoa2212948
doi: 10.1212/WNL.0000000000007852 37. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early
symptomatic Alzheimer disease the TRAILBLAZER-ALZ 2
25. Brookmeyer R, Corrada MM, Curriero FC, Kawas C.
Survival following a diagnosis of Alzheimer disease. Arch randomized clinical trial. JAMA. 2023;330:512-527.
Neurol. 2002;59:1764-1767. doi: 10.1001/jama.2023.13239

Volume 3 Issue 2 (2024) 10 doi: 10.36922/an.3122